Nanoerythrosomes, a new derivative of erythrocyte ghost II: Identification of the mechanism of action

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2831-2836

  Moorjani, Mira ^b   Lejeune, Agnès ^a   Gicquaud, Claude ^a   Lacroix, Jacques ^b   Poyet, Patrick ^b   C Gaudreault, René ^b  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b Centre de Recherche du CHUQ HSFA   (Canada)

Author keywords

Cancer treatment; Daunorubicin; Drug delivery system; Erythrosome derivatives; Nanoerythrosomes; Red blood cell derivatives

Indexed keywords

DAUNORUBICIN; DRUG CARRIER; GLUTARALDEHYDE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG ADSORPTION; DRUG DIFFUSION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG RELEASE; ENDOCYTOSIS; ERYTHROCYTE GHOST; ERYTHROCYTE MEMBRANE; FLUORESCENCE MICROSCOPY; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; ERYTHROCYTE MEMBRANE; LEUKEMIA P388; LYSOSOMES;

EID: 0029859068     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gregoriadis G: In: Targeting of drugs: Anatomical and physiological considerations (Gregoriadis G and Poste G, eds). London. Plenum Press, 1988.
2. Gregoriadis G: In: Targeting of drugs (Gregoriadis G, Seniar J, Trouet A, eds). NewYork, Plenum Press, 1982.
3. Vaizoglu MO, Speiser PP: Pharmacosomes- A novel drug delivery system. Acta Pharm Suec 23: 163-172, 1986.
4. Widder KJ, Senyei AE, Ranney DF: In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Res 40: 3512-3717, 1980.
5. Puisieux F: Liposomes and their use in therapeutics- Overview of research to date. In: Liposomes (Puisieux F and Delattre J, eds). Paris, Rech Doc Lavoisier, 1985, pp 205-253.
6. Kazuo M, Unezaki S, Takahasi N, Iwatsuru M: Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim Biophys Acta 1149: 209-216, 1993.
7. Gregoriadis G, McCormack B, Poste G: Targeting of drugs 4: Advances in system construction (Gregoriadis G and Poste G, eds). London, Plenum Press. (1995).
8. Lejeune A, Moorjani M, Gicquaud C, Lacroix J. Poyet P and C.-Gaudreault, R: Nanoerythrosome, a new derivative of erythrocyte ghost: Preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res 14: 915-920, 1994.
9. Burke T and Tritton T: Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles:an equilibrium binding study. Biochemistry 24: 1768-1776, 1985.4
10. Shen W-C and Ryser J-P: Cis-aconitic spacer between daunorubicin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Comm 102: 1048-1054, 1981.
11. Carmichael J, De Graff WG, Gazdar AF, Minna ID and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
12. Page M, Bejaoui N, Cinq-Mars B and Lemieux P: Optimisation of the tetrazolium-based colorimetric assay for the measurement of number and cytotoxidty. Int J Immunopharmacol 10: 785-793, 1988.
13. Dillman R, Johnson D, Shawler D and Koziol J: Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug, Cancer Res 48: 6097-6102, 1988.